Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02367911 · ClinicalTrials.gov registry record · Phase 3
A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis
A Phase 3 study of Plaque Psoriasis, sponsored by Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 144
- Enrollment target
- 9
- Study locations
NCT02367911: Completed Phase 3 study of Plaque Psoriasis, sponsored by Therapeutics.
NCT02367911 is a Phase 3 study of Plaque Psoriasis that has completed, run by Therapeutics. The registered enrollment target is 144 participants, below the 413-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (65% lower). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02367911, a Phase 3 study of Plaque Psoriasis, has completed, sponsored by Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 144 participants
- Enrollment target
- 9
- Study locations
Study Summary
This Phase 3 study has been designed to determine and compare the efficacy and safety of 122-0551 Foam and Vehicle Foam applied twice daily for two weeks in subjects with plaque psoriasis.
Primary Outcome
The IGA score is a static evaluation of the overall or "average" degree of severity of a subject's disease, taking into account all of the subject's psoriatic lesions. "Treatment success" is defined as a score of 0 or 1 representing "cleared" or "almost cleared" at Day 15 with at least a two grade decrease in severity score relative to Baseline. IGA is measured on a 5-point scale, ranging from 0 (clear) to 4 (severe).
Conditions Studied
Interventions
- DRUG Vehicle Foam
- DRUG 122-0551 Foam
Study Locations (9)
Indiana
- Shideler Clinical Research Center - Carmel
- The Indiana Clinical Trials Center, PC - Plainfield
Alabama
- Total Skin and Beauty Dermatology Center, PC - Birmingham
California
- UCSD Dermatology - San Diego
Florida
- Leavitt Medical Associates of Florida d/b/a Ameriderm Research - Ormond Beach
Michigan
- Henry Ford Health System - Detroit
Missouri
- MediSearch Clinical Trials - Saint Joseph
North Carolina
- Dermatology Consulting Services - High Point
Texas
- Arlington Research Center, Inc. - Arlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2015-01 |
| Est. Completion | 2017-02 |
| Phase | Phase 3 |
What the finished NCT02367911 record still lists
NCT02367911 is an interventional study that assigns participants to a tested intervention. The registered 144 participants enrollment target is mid-sized for trials with a published cap, below the 413-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (65% lower).
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Vehicle Foam is the first listed.
NCT02367911 lists 9 locations in 8 states (Indiana, Alabama, California).
Frequently Asked Questions
What is clinical trial NCT02367911 about?
NCT02367911 is a clinical study titled "A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis". This Phase 3 study has been designed to determine and compare the efficacy and safety of 122-0551 Foam and Vehicle Foam applied twice daily for two weeks in subjects with plaque psoriasis.
What is the current status of trial NCT02367911?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 144 participants. The study started on 2015-01. Estimated completion is 2017-02.
What conditions does trial NCT02367911 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT02367911?
The interventions under investigation include: Vehicle Foam (DRUG), 122-0551 Foam (DRUG).
Who is sponsoring clinical trial NCT02367911?
This trial is sponsored by Therapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02367911 being conducted?
This trial has 9 study locations across Alabama, California, Florida, Indiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02367911's enrollment target sits among peer trials
144 26th of 45 higher than 20 of 45 other Plaque Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Plaque Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
RECRUITING · Phase 3
-
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
ACTIVE NOT RECRUITING · Phase 3
-
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01861106 · 144 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- NCT03482245 · 144 participants · NA
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
- NCT03504683 · 144 participants · NA
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes
- NCT03905603 · 144 participants · Early Phase 1
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia